Background: Tuberculosis (TB) is one of the top lethal infectious diseases worldwide. In recent years, interferon-γ (INF-γ) release assays (IGRAs) have been established as routine tests for diagnosing TB infection. However, produced INF-γ assessment cannot permit to distinguish active ATB from latent TB infection (LTBI), especially in TB epidemic areas. In addition to IFN-γ, interleukin-2 (IL-2), secreted by activated T cells, is involved in immune response against Mycobacterium tuberculosis. This could be involved in the follow up of treatment response. The aim of our study was to determine IFN-γ and IL2 cytokines profiles of patients under antituberculosis treatment. Materials and Methods: A six months’ cross-sectional study was conducted at the Jamot Hospital of Yaoundé, from May to August 2021. Sociodemographic and clinical data as well as 5 mL of blood were collected from each participant. INF-γ and IL-2 were determined using indirect Enzyme linked Immuno-Sorbent Assay (ELISA) according to the manufacturer’s recommendations and spectrum exam in combination with radiography and GeneXpert were used as standard. P-values < 0.05 were interpreted as statistically significant. All statistical analysis was performed using SPSS version 22.0 Results: The results showed that men were more infected 14/61 (31.8%) with a high presence in active and resistant TB groups. The mean age was 41.3 ± 13.1 years with a 95% CI = [38.2 - 44.7], the age group with the highest infection rate was ranged between 31 and 40 years. The IL-2 and INF-γ means were respectively 327.6 ± 160.6 pg/mL and 26.6 ± 13.0 pg/mL in ATB patients, 251.1 ± 30.9 pg/mL and 21.4 ± 9.2 pg/mL in patients with resistant tuberculosis, while it was 149.3 ± 93.3 pg/mL and 17.9 ± 9.4 pg/mL in cured patients, 15.1 ± 8.4 pg/mL and 5.3 ± 2.6 pg/mL in participants presumed healthy (p < 0.0001). Significant differences in IFN-γ and IL-2rates were observed between the different groups. Conclusion: Monitoring the serum levels of INF-γ and IL-2 would be useful for the follow-up of anti-tuberculosis patients, particularly in the both cytokines association case.
References
[1]
Viney, K., Lowbridge, C., Morishita, F., Rahevar, K., Oh, K.H., Islam, T. and Marais, B.J. (2021) Evaluation of the 2016-2020 Regional Tuberculosis Response Framework, WHO Western Pacific Region. Bulletin of the World Health Organization, 99, 330-341. https://doi.org/10.2471/blt.20.268060
[2]
Organisation mondiale de la Santé (2020) Rapport sur la tuberculose dans le monde 2020: Résumé d’orientation. https://iris.who.int/handle/10665/337571
[3]
World Health Organization (2021) National Tuberculosis Prevalence Surveys 2007-2016. http://apps.who.int/iris
[4]
Plan Strategique National (2021) Plan Strategique National 2020-2024 du programme national de lutte contre la tuberculose. https://www.pnlt.cm/index.php/documentation/plan-strategique-national
[5]
Donkeng-Donfack, V.F., Tchatchueng-Mbougua, J.B., Abanda, N.N., Ongboulal, S.M., Djieugoue, Y.J., Kamdem Simo, Y., et al. (2022) A Cost-Benefit Algorithm for Rapid Diagnosis of Tuberculosis and Rifampicin Resistance Detection during Mass Screening Campaigns. BMC Infectious Diseases, 22, Article No. 219. https://doi.org/10.1186/s12879-022-07157-0
[6]
Goletti, D., Lindestam Arlehamn, C.S., Scriba, T.J., Anthony, R., Cirillo, D.M., Alonzi, T., et al. (2018) Can We Predict Tuberculosis Cure? What Tools Are Available? European Respiratory Journal, 52, Article 1801089. https://doi.org/10.1183/13993003.01089-2018
[7]
Lin, Y., Harries, A.D., Critchley, J.A., Owiti, P., Dejgaard, A., Kumar, A.M.V., et al. (2019) Prise en charge diabète-tuberculose: Guide des éléments essentiels pour une bonne pratique. Union Internationale Contre la Tuberculose et les Maladies Respiratoires (L´Union), Paris.
[8]
Auguste, P., Tsertsvadze, A., Pink, J., Court, R., McCarthy, N., Sutcliffe, P. and Clarke, A. (2017) Comparing Interferon-Gamma Release Assays With Tuberculin Skin Test for Identifying Latent Tuberculosis Infection That Progresses to Active Tuberculosis: Systematic Review and Meta-Analysis. BMC Infectious Diseases, 17, Article No. 200. https://doi.org/10.1186/s12879-017-2301-4
[9]
Dirix, V., Collart, P., Van Praet, A., Hites, M., Dauby, N., Allard, S., Racapé, J., Singh, M., Locht, C., Mascart, F. and Corbière, V. (2022) Immuno-Diagnosis of Active Tuberculosis by a Combination of Cytokines/Chemokines Induced by Two Stage-Specific Mycobacterial Antigens: A Pilot Study in a Low TB Incidence Country. Frontiers in Immunology, 13, Article 842604. https://doi.org/10.3389/fimmu.2022.842604
[10]
Wu, M., Li, M., Yue, Y. and Xu, W. (2016) DNA Vaccine with Discontinuous T‐cell Epitope Insertions into HSP65 Scaffold as a Potential Means to Improve Immunogenicity of Multi‐Epitope Mycobacterium Tuberculosis Vaccine. Microbiology and Immunology, 60, 634-645. https://doi.org/10.1111/1348-0421.12410
[11]
Tékpa, G., Fikouma, V., Marada Téngothi, R.M., Longo, J.d.D., Amakadé Woyengba, A.P. and Koffi, B. (2019) Aspects épidémiologiques et cliniques de la tuberculose en milieu hospitalier à bangui. Pan African Medical Journal, 33, Article 31. https://doi.org/10.11604/pamj.2019.33.31.13442
[12]
Nguepy Keubo, F.R., Djifack Tadongfack, T., Tsafack, J., Djoufack, G. and Bianke, P. (2018) Clinical Profile of Patients with Tuberculosis in Dschang, Cameroon: Role of the Therapeutic Path in Delaying Diagnosis. Médecine et Santé Tropicales, 28, 399-403. https://doi.org/10.1684/mst.2018.0859
[13]
Ndishimye, P., Domokos, B., Stillo, J., Seghrouchni, F., Mrabet, O., Homorodean, D., Pop, C.M. and Sadak, A. (2017) A Case Control Study of Risk Factors Associated with Pulmonary Tuberculosis in Romania: Experience at a Clinical Hospital of Pneumology. Medicine and Pharmacy Reports, 90, 54-59. https://doi.org/10.15386/cjmed-652
[14]
Xu, J., Li, Z., Chen, X., Shi, C., Wu, M., Chen, H., et al. (2017) More Significance of TB‐IGRA Except for the Diagnose of Tuberculosis. Journal of Clinical Laboratory Analysis, 32, e22183. https://doi.org/10.1002/jcla.22183
[15]
Hussain, S., Afzal, N., Javaid, K., Ullah, M.I. and Ahmad, T. (2010) Level of Interferon Gamma in the Blood of Tuberculosis Patients. Iranian Journal of Immunology, 7, 240-246.
[16]
Chegou, N.N., Heyckendorf, J., Walzl, G., Lange, C. and Ruhwald, M. (2013) Beyond the IFN-γHorizon: Biomarkers for Immunodiagnosis of Infection with Mycobacterium tuberculosis. European Respiratory Journal, 43, 1472-1486. https://doi.org/10.1183/09031936.00151413
[17]
Mamishi, S., Pourakbari, B., Teymuri, M., Rubbo, P.-A., Tuaillon, E., Keshtkar, A.A. and Mahmoudi, S. (2014) Diagnostic Accuracy of IL-2 for the Diagnosis of Latent Tuberculosis: A Systematic Review and Meta-Analysis. European Journal of Clinical Microbiology & Infectious Diseases, 33, 2111-2119. https://doi.org/10.1007/s10096-014-2190-z
[18]
Goyal, N., Kashyap, B. and Kaur, I.R. (2016) Significance of IFN‐ɤ/IL‐2 Ratio as a Circulating Diagnostic Biomarker in Extrapulmonary Tuberculosis. Scandinavian Journal of Immunology, 83, 338-344. https://doi.org/10.1111/sji.12424
[19]
Kombila, U.D., Kane, Y.D., Rassoule Mbaye, F.B., Diouf, N.F., Ka, W. and Touré, N.O. (2018) Particularités radiologiques de la tuberculose pulmonaire à microscopie positive au Service de Pneumologie du Centre Hospitalier National Universitaire de FANN (CHNUF), Dakar (Sénégal). Pan African Medical Journal, 30, Article 21. https://doi.org/10.11604/pamj.2018.30.21.14208
[20]
Qiu, X., Wang, H., Tang, Y., Su, X., Ge, L., Qu, Y. and Mu, D. (2020) Is Interleukin-2 an Optimal Marker for Diagnosing Tuberculosis Infection? A Systematic Review and Meta-Analysis. Annals of Medicine, 52, 376-385. https://doi.org/10.1080/07853890.2020.1800073
[21]
Won, E., Choi, J., Cho, Y., Jin, H., Kee, H.J., Park, Y., Kwon, Y. and Kee, S. (2017) Biomarkers for Discrimination between Latent Tuberculosis Infection and Active Tuberculosis Disease. Journal of Infection, 74, 281-293. https://doi.org/10.1016/j.jinf.2016.11.010
